PE20050588A1 - Composicion para liberacion sostenida que comprende pitavastatina - Google Patents
Composicion para liberacion sostenida que comprende pitavastatinaInfo
- Publication number
- PE20050588A1 PE20050588A1 PE2004001169A PE2004001169A PE20050588A1 PE 20050588 A1 PE20050588 A1 PE 20050588A1 PE 2004001169 A PE2004001169 A PE 2004001169A PE 2004001169 A PE2004001169 A PE 2004001169A PE 20050588 A1 PE20050588 A1 PE 20050588A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- amount
- pitavastatin
- internal
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION SOSTENIDA QUE COMPRENDE COMO INGREDIENTE ACTIVO PITAVASTATIN O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, DICHA COMPOSICION COMPRENDE UN NUCLEO QUE CONSISTE EN UNA FASE INTERIOR (INTERNA) Y UNA FASE EXTERNA (EXTERNA) DONDE LA FASE EXTERNA NO COMPRENDE UNA UNA SUSTANCIA FORMADORA DE LA MATRIZ Y EL NUCLEO ES PRIMERO RECUBIERTO DE UN RECUBRIMIENTO LAMINADO NO FUNCIONAL Y LUEGO DE UN RECUBRIMIENTO ENTERICO. LA CANTIDAD DE PITAVASTATIN O LA SAL FARMACEUTICA ACEPTABLE ES DE 1% A 59 % POR PESO DE LA COMPOSICION DEL NUCLEO SIENDO UN PORCENTAJE PREFERIDO DE 5% A 50% POR PESO DE LA COMPOSICION DEL NUCELO. LA CANTIDAD DE PITAVASTATIN ES DE 1mg A 32mg. LA FASE INTERNA COMPRENDE UNA SUSTANCIA FORMADORA DE LA MATRIZ SELECCIONADA DE POLIETILENGLICOL, POLIVINILPIRROLIDONA, HIDROXIPROPILMETILCELULOSA, ENTRE OTROS Y DICHA SUSTANCIA TIENE UNA VISCOSIDAD DE 1 A 100,000 cps. LA COMPOSICION COMPRENDE ADEMAS DE 1% A 15% EN PESO DE UN ESTABILIZADOR COMO ALUMINOMETASILICATO DE MAGNESIO (NEUSILIN). EL RECUBRIMIENTO NO FUNCIONAL COMPRENDE HIDROXIPROPILMETILCELULOSA, DIOXIDO DE TITANIO, POLIETILENGLICOL Y TALCO EN UNA CANTIDAD DE 4mg DE LAMINA POR cm2. EL RECUBRIMIENTO ENTERICO ES SELECCIONADO DE EUDAGRIT L30D (COPOLIMERO METACRILICO) TALCO Y POLIETILENGLICOL EN UNA CANTIDAD DE 4mg A 6mg DE POLIMERO POR cm2. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE HIPERLIPIDEMIA, HIPERCOLESTEROLEMIA Y ARTEROSCLEROSIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52537303P | 2003-11-26 | 2003-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050588A1 true PE20050588A1 (es) | 2005-09-05 |
Family
ID=34632977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001169A PE20050588A1 (es) | 2003-11-26 | 2004-11-26 | Composicion para liberacion sostenida que comprende pitavastatina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070218134A1 (es) |
| EP (1) | EP1689398A2 (es) |
| JP (1) | JP2007512287A (es) |
| KR (1) | KR20060118507A (es) |
| CN (1) | CN1905880A (es) |
| AR (1) | AR046458A1 (es) |
| AU (1) | AU2004292768B2 (es) |
| BR (1) | BRPI0417011A (es) |
| CA (1) | CA2546244A1 (es) |
| MX (1) | MXPA06005953A (es) |
| MY (1) | MY147202A (es) |
| PE (1) | PE20050588A1 (es) |
| RU (1) | RU2006122630A (es) |
| TW (1) | TW200534876A (es) |
| WO (1) | WO2005051346A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048413B2 (en) * | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CN102048701B (zh) * | 2010-11-29 | 2013-01-09 | 青岛黄海制药有限责任公司 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
| WO2012141160A1 (ja) * | 2011-04-12 | 2012-10-18 | 沢井製薬株式会社 | ピタバスタチン含有製剤及びその製造方法 |
| WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| PT2959892T (pt) | 2013-02-22 | 2020-12-15 | Zeria Pharm Co Ltd | Comprimido com revestimento entérico |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| CN111053752A (zh) * | 2018-10-16 | 2020-04-24 | 南京卓康医药科技有限公司 | 一种稳定的匹伐他汀钙的肠溶片及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| PL365696A1 (en) * | 2000-04-12 | 2005-01-10 | Novartis Ag | Combination of organic compounds |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| CA2450820C (en) * | 2001-08-16 | 2011-03-15 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
-
2004
- 2004-11-24 MY MYPI20044867A patent/MY147202A/en unknown
- 2004-11-25 CN CNA2004800409427A patent/CN1905880A/zh active Pending
- 2004-11-25 EP EP04819224A patent/EP1689398A2/en not_active Withdrawn
- 2004-11-25 US US10/580,895 patent/US20070218134A1/en not_active Abandoned
- 2004-11-25 RU RU2006122630/15A patent/RU2006122630A/ru not_active Application Discontinuation
- 2004-11-25 MX MXPA06005953A patent/MXPA06005953A/es active IP Right Grant
- 2004-11-25 KR KR1020067010228A patent/KR20060118507A/ko not_active Application Discontinuation
- 2004-11-25 JP JP2006540391A patent/JP2007512287A/ja active Pending
- 2004-11-25 AR ARP040104363A patent/AR046458A1/es not_active Application Discontinuation
- 2004-11-25 BR BRPI0417011-3A patent/BRPI0417011A/pt not_active IP Right Cessation
- 2004-11-25 WO PCT/EP2004/013419 patent/WO2005051346A2/en active Application Filing
- 2004-11-25 AU AU2004292768A patent/AU2004292768B2/en not_active Ceased
- 2004-11-25 TW TW093136328A patent/TW200534876A/zh unknown
- 2004-11-25 CA CA002546244A patent/CA2546244A1/en not_active Abandoned
- 2004-11-26 PE PE2004001169A patent/PE20050588A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1905880A (zh) | 2007-01-31 |
| BRPI0417011A (pt) | 2007-02-21 |
| CA2546244A1 (en) | 2005-06-09 |
| KR20060118507A (ko) | 2006-11-23 |
| AU2004292768A1 (en) | 2005-06-09 |
| MY147202A (en) | 2012-11-14 |
| RU2006122630A (ru) | 2008-01-10 |
| US20070218134A1 (en) | 2007-09-20 |
| JP2007512287A (ja) | 2007-05-17 |
| WO2005051346A3 (en) | 2005-08-25 |
| WO2005051346A2 (en) | 2005-06-09 |
| AR046458A1 (es) | 2005-12-07 |
| EP1689398A2 (en) | 2006-08-16 |
| AU2004292768B2 (en) | 2009-04-02 |
| MXPA06005953A (es) | 2006-07-06 |
| TW200534876A (en) | 2005-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200379T1 (hr) | Spojevi pirimidindiona protiv srčanih stanja | |
| ES2487244T3 (es) | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| ECSP034639A (es) | Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| AR088875A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion | |
| FI3154594T3 (fi) | Fap-aktivoituja terapeuttisia aineita ja niihin liittyviä käyttöjä | |
| CO2021007447A2 (es) | Métodos de tratamiento para la fibrosis quística | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| DE60330144D1 (de) | Beschichtung von stents mit verzögerter wirkstofffreisetzung | |
| PE20050588A1 (es) | Composicion para liberacion sostenida que comprende pitavastatina | |
| AR065120A1 (es) | Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| AR074471A1 (es) | Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer | |
| HK1089950A1 (en) | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form | |
| PE20110432A1 (es) | Etexilato de dabigatran o una sal del mismo | |
| PE20071337A1 (es) | Nanoparticulas que comprenden imatinib, composiciones farmaceuticas y dispositivos que comprenden dichas nanoparticulas y uso farmaceutico de las mismas | |
| TW200722088A (en) | Diabetes remedy | |
| EE200400110A (et) | Reguleeritud/pikendatud vabanemisega tahke ravimvorm kui doosi dumpingu vähendatud riskiga uus ravimi manustamissüsteem | |
| PE20020385A1 (es) | Composicion farmaceutica que comprende un nucleo de eletriptan capaz de conseguir un curso sigmoideo de liberacion controlada | |
| CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
| CL2011000187A1 (es) | Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii. | |
| AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| CR9839A (es) | Composicion farmaceutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpetica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |